Sagimet - SGMT Quarterly EPS earnings growth

Sagimet Biosciences Inc - graphic logo of issuer SGMT

Positive sentiment is driven by successful interim results from Phase 2b, although the business's success depends on overcoming regulatory barriers and scaling production. The relative quarterly change in EPS demonstrates earnings dynamics, with the current figure standing at 22.90. Sagimet Biosciences (SGMT) has earned recognition from physicians as an innovator in liver disease therapy, offering hope for recovery from NASH.

Sagimet Biosciences Inc. (SGMT) - Year-over-year earnings per share growth for the last twelve months from 02/21/2024 to 11/18/2026

Financial and market metric breakdowns for Sagimet Biosciences (SGMT)

- share price and consensus valuation forecast:
Analysis of all company metrics:Sagimet Biosciences
Manufactured product of Sagimet Biosciences Inc

Sagimet Biosciences (SGMT) is currently perceived by the market as a potential leader in liver disease therapy. The quarterly EPS trend reflects the percentage change in net income per share compared to the same period last year. This metric measures the efficiency of business capitalization and reacts sensitively to operating losses. Monitoring negative values helps avoid a value trap when searching for a bottom. High brand confidence makes this indicator a key criterion for asset reliability.

Competitors of Sagimet Biosciences (SGMT)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS